Skip to Content

New Drug Approvals Archive - May 2016

See also: New Indications and Dosage Forms for May 2016

May 2016

Ameluz (aminolevulinic acid) Gel - formerly BF-200 ALA

Date of Approval: May 10, 2016
Company: Biofrontera AG
Treatment for: Actinic Keratosis

Ameluz (aminolevulinic acid) is a porphyrin precursor used in combination with the BF-RhodoLED lamp for photodynamic therapy (PDT) treatment of actinic keratoses on the face and scalp.

Tecentriq (atezolizumab) Injection

Date of Approval: May 18, 2016
Company: Genentech, Inc.
Treatment for: Bladder Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Small Cell Lung Cancer

Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of advanced urothelial carcinoma; the treatment of metastatic non-small cell lung cancer (NSCLC); extensive-stage small cell lung cancer; and for use in combination with Abraxane for the treatment of metastatic triple-negative breast cancer.

Afstyla (antihemophilic factor (recombinant), single chain) for Injection

Date of Approval: May 25, 2016
Company: CSL Behring
Treatment for: Hemophilia A

Afstyla (antihemophilic factor (recombinant), single chain, is a recombinant, antihemophilic factor indicated for the control and prevention of bleeding episodes in adults and children with hemophilia A.

Probuphine (buprenorphine) Implant

Date of Approval: May 26, 2016
Company: Titan Pharmaceuticals, Inc.
Treatment for: Opiate Dependence

Probuphine (buprenorphine) is an opioid partial agonist subdermal implant for the treatment of opioid dependence.

Ocaliva (obeticholic acid) Tablets

Date of Approval: May 27, 2016
Company: Intercept Pharmaceuticals, Inc.
Treatment for: Biliary Cirrhosis

Ocaliva (obeticholic acid) is a first-in-class farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis.

Axumin (fluciclovine F 18) Injection

Date of Approval: May 27, 2016
Company: Blue Earth Diagnostics, Ltd.
Treatment for: Diagnostic

Axumin (fluciclovine F 18) a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected recurrent prostate cancer.

Zinbryta (daclizumab) Injection

Date of Approval: May 27, 2016
Company: AbbVie, Inc. and Biogen
Treatment for: Multiple Sclerosis

Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.